Effect of meta-chlorophenylpiperazine and cholecystokinin on food intake of osborne-mendel and S5B/P1 rats

Obesity

Volumn 15, Issue 3, 2007, Pages 624-631

  White, Christy L ^a,b   Ishihara, Yuri ^a   York, David A ^a   Bray, George A ^a  

^a Louisiana State University System   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Dietary induced obesity; Fat intake; Osborne mendel; S5B PL; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1-(3-CHLOROPHENYL)PIPERAZINE; CHOLECYSTOKININ; GASTROINTESTINAL AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; ATHEROGENIC DIET; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EATING; LOW FAT DIET; MALE; RAT; RAT STRAIN;

ANIMALS; CHOLECYSTOKININ; DIET, ATHEROGENIC; DIET, FAT-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; GASTROINTESTINAL AGENTS; MALE; PIPERAZINES; RATS; RATS, INBRED STRAINS; RECEPTOR, SEROTONIN, 5-HT2C;

ANIMALIA; RATTUS;

EID: 34247341794     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.579     Document Type: Article

References (45)

1. Astrup A, Grunwald GK, Melanson EL, Saris WH, Hill JO. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord. 2000;24:1545-52.
2. Bray GA, Popkin BM. Dietary fat intake does affect obesity! Am J Clin Nutr. 1998;68:1157-73.
3. Golay A, Bobbioni E. The role of dietary fat in obesity. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):2-11.
4. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention prog on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69:632-46.
5. Okada S, York DA, Bray GA, Mei J, Erlanson-Albertsson C. Differential inhibition of fat intake in two strains of rat by the peptide enterostatin. Am J Physiol. 1992;262:R1111-6.
6. Fisler JS, Underberger SJ, York DA, Bray GA. d-Fenfluramine in a rat model of dietary fat-induced obesity. Pharmacol Biochem Behav. 1993;45:487-93.
7. Schemmel RA, Teague RJ, Bray GA. Obesity in Osborne-Mendel and S 5B/P1 rats: effects of sucrose solutions, castration, and treatment with estradiol or insulin. Am J Physiol. 1982;243:R347-53.
8. Ishihara Y, White CL, Kageyama H, Kageyama A, York DA, Bray GA. Effects of diet and time of the day on serum and CSF leptin levels in Osborne-Mendel and S5B/P1 rats. Obes Res. 2004;12:1067-76.
9. Lin L, York DA, Bray GA. Comparison of Osborne-Mendel and S5B/PL strains of rat: central effects of galanin NPY, beta-casomorphin and CRH on intake of high-fat and low-fat diets. Obes Res. 1996;4:117-24.
10. White CL, Ishihara Y, Dotson TL, Hughes DA, Bray GA, York DA. Effect of a beta-3 agonist on food intake in two strains of rats that differ in susceptibility to obesity. Physiol Behav. 2004;82:489-96.
11. White CL, Ishii Y, Mendoza T, et al. Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity. Peptides. 2005;26:2331-8.
12. Liu X, York DA, Bray GA. Regulation of ghrelin gene expression in stomach and feeding response to a ghrelin analogue in two strains of rats. Peptides. 2004;25:2171-7.
13. Shimizu H, Fisler S, Bray GA. Extracellular hypothalamic monoamines measured by in vivo microdialysis in a rat model of dietary fat-induced obesity. Obes Res. 1994;2:100-9.
14. Smith BK, York DA, Bray GA. Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. Am J Physiol. 1999;277:R802-11.
15. Smith BK, York DA, Bray GA. Chronic d-fenfluramine treatment reduces fat intake independent of macronutrient preference. Pharmacol Biochem Behav. 1998;60:105-14.
16. Gilbertson TA, Liu L, York DA, Bray GA. Dietary fat preferences are inversely correlated with peripheral gustatory fatty acid sensitivity. Ann NY Acad Sci. 1998;855:165-8.
17. Greenberg D, McCaffery J, Potack JZ, Bray GA, York DA. Differential satiating effects of fats in the small intestine of obesity-resistant and obesity-prone rats. Physiol Behav. 1999;66:621-6.
18. Gilbertson TA, Liu L, Kim I, Burks CA, Hansen DR. Fatty acid responses in taste cells from obesity-prone and -resistant rats. Physiol Behav. 2005;86:681-90.
19. Kennett GA, Wood MD, Glen A, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol. 1994;111:797-802.
20. Smith GP, Gibbs J. Satiating effect of cholecystokinin. Ann NY Acad Sci. 1994;713:236-41.
21. Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S. Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol. 1979;308:159-63.
22. Lin L, Chen J, York DA. Chronic ICV enterostatin preferentially reduced fat intake and lowered body weight. Peptides. 1997:18:657-61.
23. Kennett GA, Whitton P, Shah K, Curzon G. Anxiogeniclike effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol. 1989;164:445-54.
24. Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Br J Pharmacol. 1991;103:2016-20.
25. Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997;36:609-20.
26. Fone KC, Austin RH, Topham IA, Kennett GA, Punhani T. Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. Br J Pharmacol. 1998;123:1707-15.
27. Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Bed). 1994;116:120-2.
28. Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol. 1988;94:137-47.
29. Whitton P, Curzon G. Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology (Bed). 1990;100:138-40.
30. Aulakh CS, Wozniak KM, Hill JL, Devane CL, Tolliver TJ, Murphy DL. Differential neuroendocrine responses to the 5-HT agonist m- chlorophenylpiperazine in Fawn-Hooded rats relative to Wistar and Sprague-Dawley rats. Neuroendocrinology. 1988;48:401-6.
31. Halford JC, Blundell JE. Metergoline antagonizes fluoxetine-induced suppression of food intake but not changes in the behavioural satiety sequence. Pharmacol Biochem Behav. 1996;54:745-51.
32. Yen TT, Fuller RW. Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss. Am J Clin Nutr. 1992;55:177S-80S.
33. White CL, Kashima K, Bray GA, York DA. Effect of a serotonin 1-A agonist on food intake of Osborne-Mendel and S5B/P1 rats. Physiol Behav. 2000;68:715-22.
34. Fisler JS, Shimizu H, Bray GA. Brain 3-hydroxybutyrate, glutamate, and GABA in a rat model of dietary obesity. Physiol Behav. 1989;45:571-7.
35. Schaffhauser AO, Madiehe AM, Braymer HD, Bray GA, York DA. Effects of a high-fat diet and strain on hypothalamic gene expression in rats. Obes Res. 2002; 10:1188-96.
36. Burton-Freeman B, Gietzen DW, Schneeman BO. Cholecystokinin and serotonin receptors in the regulation of fatinduced satiety in rats. Am J Physiol. 1999;276:R429-34.
37. Grignaschi G, Mantelli B, Fracasso C, Anelli M, Caccia S, Samanin R. Reciprocal interaction of 5-hydroxytryptamine and cholecystokinin in the control of feeding patterns in rats. Br J Pharmacol. 1993;109:491-4.
38. Stallone D, Nicolaidis S, Gibbs J. Cholecystokinin-induced anorexia depends on serotoninergic function. Am J Physiol. 1989;256:R1138-41.
39. Poeschla B, Gibbs J, Simansky KJ, Greenberg D, Smith GP. Cholecystokinin-induced satiety depends on activation of 5-HT1C receptors. Am J Physiol. 1993;264:R62-4.
40. Cooper SJ, Dourish CT, Barber DJ. Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329. Br J Pharmacol. 1990;99:65-70.
41. Douglas BR, Jansen JB, de Jong AJ, Lamers CB. Effect of various triglycerides on plasma cholecystokinin levels in rats. J Nutr. 1990;120:686-90.
42. Douglas BR, Woutersen RA, Jansen JB, de Jong AJ, Lamers CB. The influence of different nutrients on plasma cholecystokinin levels in the rat. Experientia. 1988;44:21-3.
43. Hildebrand P, Beglinger C, Gyr K, et al. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest. 1990;85:640-6.
44. Lewis DRP, Greenberg D. Increasing the unsaturation of a fatty acid increases it satiating potency in rats. Soc Neurosci Abstr. 1990;16:295.
45. Yox DP, Stokesberry H, Ritter RC. Suppression of sham feeding by intraintestinal oleate: blockade by a CCK antagonist and reversal of blockade by exogenous CCK-8. In: Hughes JD, Woodruff G, eds. The Neuropeptide Cholecystokinin (CCK), Anatomy, and Biochemistry, Receptors, Pharmacology and Physiology. Chichester: Ellis Horwood; 1989.